Familiar dermatologic drugs as therapies for COVID-19()

Researchers the world over are working to find the treatments needed to reduce the negative effects of coronavirus disease 2019 (COVID-19) and improve the current prognosis of patients. Several drugs that are often used in dermatology are among the potentially useful treatments: ivermectin, antiandr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ortega-Peña, M., González-Cuevas, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AEDV. Published by Elsevier España, S.L.U. 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756155/
http://dx.doi.org/10.1016/j.adengl.2020.09.015
_version_ 1783626480003055616
author Ortega-Peña, M.
González-Cuevas, R.
author_facet Ortega-Peña, M.
González-Cuevas, R.
author_sort Ortega-Peña, M.
collection PubMed
description Researchers the world over are working to find the treatments needed to reduce the negative effects of coronavirus disease 2019 (COVID-19) and improve the current prognosis of patients. Several drugs that are often used in dermatology are among the potentially useful treatments: ivermectin, antiandrogenic agents, melatonin, and the antimalarial drugs chloroquine and hydroxychloroquine. These and other agents, some of which have proven controversial, are being scrutinized by the scientific community. We briefly review the aforementioned dermatologic drugs and describe the most recent findings relevant to their use against COVID-19.
format Online
Article
Text
id pubmed-7756155
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AEDV. Published by Elsevier España, S.L.U.
record_format MEDLINE/PubMed
spelling pubmed-77561552020-12-23 Familiar dermatologic drugs as therapies for COVID-19() Ortega-Peña, M. González-Cuevas, R. Actas Dermosifiliogr Review Researchers the world over are working to find the treatments needed to reduce the negative effects of coronavirus disease 2019 (COVID-19) and improve the current prognosis of patients. Several drugs that are often used in dermatology are among the potentially useful treatments: ivermectin, antiandrogenic agents, melatonin, and the antimalarial drugs chloroquine and hydroxychloroquine. These and other agents, some of which have proven controversial, are being scrutinized by the scientific community. We briefly review the aforementioned dermatologic drugs and describe the most recent findings relevant to their use against COVID-19. AEDV. Published by Elsevier España, S.L.U. 2021-02 2020-12-23 /pmc/articles/PMC7756155/ http://dx.doi.org/10.1016/j.adengl.2020.09.015 Text en © 2020 AEDV. Published by Elsevier España, S.L.U. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review
Ortega-Peña, M.
González-Cuevas, R.
Familiar dermatologic drugs as therapies for COVID-19()
title Familiar dermatologic drugs as therapies for COVID-19()
title_full Familiar dermatologic drugs as therapies for COVID-19()
title_fullStr Familiar dermatologic drugs as therapies for COVID-19()
title_full_unstemmed Familiar dermatologic drugs as therapies for COVID-19()
title_short Familiar dermatologic drugs as therapies for COVID-19()
title_sort familiar dermatologic drugs as therapies for covid-19()
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756155/
http://dx.doi.org/10.1016/j.adengl.2020.09.015
work_keys_str_mv AT ortegapenam familiardermatologicdrugsastherapiesforcovid19
AT gonzalezcuevasr familiardermatologicdrugsastherapiesforcovid19

Ejemplares similares